Xipere Injection, Suspension
NDC Package 24208-040-01
Package Information
Xipere (triamcinolone acetonide) injection is a medication used in a variety of conditions such as allergic disorders, arthritis, gout, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, collagen and skin diseases. This formulation utilizes a injection, suspension delivery system. Marketed by Bausch & Lomb Incorporated, this product is identified by NDC 24208-040 and is authorized under FDA application NDA211950.
Identification & Billing
- RxCUI: 2585221 - triamcinolone acetonide 40 MG in 0.9 ML Injection
- RxCUI: 2585221 - 0.9 ML triamcinolone acetonide 40 MG/ML Injection
- RxCUI: 2585221 - triamcinolone acetonide 40 MG per 0.9 ML Injection
- RxCUI: 2585226 - XIPERE 40 MG in 0.9 ML Injection
- RxCUI: 2585226 - 0.9 ML triamcinolone acetonide 40 MG/ML Injection [Xipere]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24208 - Bausch & Lomb Incorporated
- 24208-040 - Xipere
- 24208-040-01 - 1 TRAY in 1 CARTON / 1 VIAL in 1 TRAY / .9 mL in 1 VIAL (24208-040-02)
- 24208-040 - Xipere
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (24208-040). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24208-040-01 identifies a specific commercial package of 1 tray in 1 carton / 1 vial in 1 tray / .9 ml in 1 vial (24208-040-02) of Xipere, a human prescription drug labeled by Bausch & Lomb Incorporated. This injection, suspension is formulated for ophthalmic use and contains triamcinolone acetonide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch & Lomb Incorporated on December 17, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used in a variety of conditions such as allergic disorders, arthritis, gout, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, collagen and skin diseases. Talk to your doctor about the risks and benefits of triamcinolone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use. Triamcinolone is known as a corticosteroid hormone (glucocorticoid). It works by decreasing your body's immune response to these diseases and reduces symptoms such as swelling.
How is this Bausch & Lomb Incorporated product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24208004001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
